Our goal is to improve the lives of patients from early childhood through adulthood by leveraging our pharmaceutical and clinical development expertise to develop pediatric-friendly therapeutics that address critical unmet medical needs in the field of rare and orphan diseases.
Distal Renal Tubular Acidosis is a disease affecting the distal tubule of the kidney. It is an orphan disease which can be either genetic in origin or acquired. Currently there are no approved treatments for dRTA. Watch the video for more information.
Our most advanced product, ADV7103, is an innovative combination product being developed for the treatment of distal Renal Tubular Acidosis (dRTA), as well as a second indication, Cystinuria, an inherited renal tubulopathy.
Stay up to date on current developments with Advicenne’s latest press releases.
Advicenne is a specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications.
Our goal is to improve the lives of patients from early childhood through adulthood by addressing critical unmet needs in the field of orphan nephrology.